Is PD-1 blockade a potential therapy for HBV?

Affiliations

¹ Centre Hépatobiliaire, Paul Brousse Hospital, Inserm-Paris Sud Research Unit 1193, University Paris Sud, Villejuif, Paris, France.
² Virology Laboratory Genomics and Health Area FISABIO - Public Health, Generalitat Valenciana, Valencia, Spain.

Editorial

Cyrille Féray et al. JHEP Rep. 2019.

. 2019 Aug 28;1(3):142-144.

doi: 10.1016/j.jhepr.2019.07.007. eCollection 2019 Sep.

¹ Centre Hépatobiliaire, Paul Brousse Hospital, Inserm-Paris Sud Research Unit 1193, University Paris Sud, Villejuif, Paris, France.
² Virology Laboratory Genomics and Health Area FISABIO - Public Health, Generalitat Valenciana, Valencia, Spain.

No abstract available

Comment on

HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection.
Ferrando-Martinez S, Huang K, Bennett AS, Sterba P, Yu L, Suzich JA, Janssen HLA, Robbins SH. Ferrando-Martinez S, et al. JHEP Rep. 2019 Jun 28;1(3):170-178. doi: 10.1016/j.jhepr.2019.06.001. eCollection 2019 Sep. JHEP Rep. 2019. PMID: 32039367 Free PMC article.

1. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol. 2006;1:23–61. - PubMed
1. Milich DR. Is the function of the HBeAg really unknown? Hum Vaccin Immunother. 2019:1–5. - PMC - PubMed
1. Lan P, Zhang C, Han Q, Zhang J, Tian Z. Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance. Hepatology. 2013;58:73–85. - PubMed
1. Wang H, Wu B, Li L, Hu L, Lin J, Jiang C. Hepatic expansion of virus-specific CD8(+)BTLA(+) T cells with regulatory properties in chronic hepatitis B virus infection. Cell Immunol. 2017;311:36–45. - PubMed
1. Salimzadeh L, Le Bert N, Dutertre CA. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest. 2018;128:4573–4587. - PMC - PubMed